It was a pleasure to speak with Dr David Hunter (Harvard Medical School, Boston, MA, USA) about the Luminopia One Amblyopia Vision Improvement Study, which were presented at AAPOS 2021.
Questions
- What are the aims and design of the Luminopia One Amblyopia Vision Improvement Study?
- What are the primary and secondary outcome measures of the study?
- What have been the findings of the study to date?
Speaker Disclosure: David Hunter discloses the following: Advisor and equity holder, Luminopia, Inc. Board member and equity holder, Rebion Inc.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of AAPOS 2021.
